Versarien PLC Appointment of Chief Technology Officer (8324K)
January 07 2021 - 2:00AM
UK Regulatory
TIDMVRS
RNS Number : 8324K
Versarien PLC
07 January 2021
7 January 2021
Versarien plc
("Versarien" or the "Company")
Appointment of Chief Technology Officer
Versarien plc (AIM: VRS), the advanced materials engineering
group, is pleased to announce that Dr Stephen Hodge has been
appointed as the Company's Chief Technology Officer ("CTO") and has
joined the Company's Board with immediate effect.
Dr Hodge is currently Head of Research at Versarien, a role he
has held since July 2018. Prior to this, he was employed as a
Principal Engineer at Cambridge Graphene Limited, a supplier of
graphene inks and other graphene materials, and a subsidiary of
Versarien. He has also held post-doctoral research associate
positions at the Cambridge Graphene Centre, a research centre
attached to the Department of Engineering at the University of
Cambridge, and in the Department of Chemistry at Imperial College
London, where he also completed a PhD in Nanomaterial
Chemistry.
Stephen is a member of the International Advisory Board for the
Graphene NOWNANO CDT at the University of Manchester and was
formerly a Teaching Fellow in the EPSRC Centre for Doctoral
Training (CDT) program in Graphene Technology at The University of
Cambridge. Stephen also holds the role of Chairman of the Technical
Working Group within the Graphene REACH registration
consortium.
Following Dr Hodge's appointment, the Company's Board now
comprises James Stewart (Non-executive Chairman), Neill Ricketts
(CEO), Christopher Leigh (CFO), Stephen Hodge (CTO), Susan Bowen
(Non-executive Director) and Iain Gray (Non-executive
Director).
Neill Ricketts, CEO of Versarien, commented: "We are delighted
to welcome Steve to the Versarien Board. He brings significant
research and scientific experience to the CTO role and will be
responsible for developing solutions and creating partnerships with
the Graphene and Plastics division's commercial pipeline.
"His academic credentials are impeccable and his time as Head of
Research at Versarien ensures that Steve will continue to
contribute to the progression of our commercial partnerships and
international expansion strategy."
Further information on Dr Stephen Hodge
Dr Stephen Anthony Hodge, aged 34, holds no other current
directorships or partnerships and has no former directorships or
partnerships within the last five years.
Dr Hodge does not hold any ordinary shares of the Company. As
part of his existing remuneration package, Dr Hodge has been
previously granted share options over the Company's ordinary shares
as follows:
a) 453,720 share options with an exercise price of 117p per share expiring in December 2028; and
b) 75,000 share options with an exercise price of 21.25p per share expiring in April 2027.
Save as disclosed above, there are no additional disclosures to
be made in accordance with Rule 17 or Schedule Two paragraph (g) of
the AIM Rules for Companies.
Enquiries:
Versarien
Neill Ricketts, CEO
Chris Leigh, CFO +44 (0)1242 269 122
SP Angel Corporate Finance (Nominated
Adviser and Joint Broker)
Matthew Johnson, Ewan Leggat, Adam Cowl +44 (0)20 3470 0470
Berenberg (Joint Broker)
Mark Whitmore, Simon Cardron +44 (0)20 3207 7800
Yellow Jersey (Investor Relations)
Charles Goodwin
Georgia Colkin
Henry Wilkinson
Versarien@yellowjerseypr.com +44 (0)774 778 8221
Notes to Editors:
Versarien Plc ( AIM:VRS ), is an advanced engineering materials
group. Leveraging proprietary technology, the Group creates
innovative engineering solutions for its clients in a diverse range
of industries.
For further information please see: http://www.versarien.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCDKABQABKDADK
(END) Dow Jones Newswires
January 07, 2021 02:00 ET (07:00 GMT)
Versarien (LSE:VRS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Versarien (LSE:VRS)
Historical Stock Chart
From Jul 2023 to Jul 2024